Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Start-Up Quarterly Statistics, Q2 2013

Sep 16 2013

• By Deanna Kamienski

Related Content

With Precedents In Place, GenSight Eyes Gene Therapies For Orphan Disorders

Apr 08 2013

Auxilium Buys Actient As Base Business Weakens

Apr 29 2013

J&J Buys Aragon, Boosting Prostate Cancer Franchise Beyond <em>Zytiga</em>

Jun 17 2013

J&J’s Boston “Deal-Making Machine” Backs Two Start-Ups

Jun 27 2013

Second Genome Scores A Deal With Janssen, A First In The Field Of Microbiome Therapeutics

Jun 06 2013

A Trio Of Strategic VCs Helps To Back Effector Therapeutics With $45 Million

May 21 2013

Related Companies

Karyopharm Therapeutics

eFFECTOR Therapeutics, Inc.

University of California San Francisco

GenSight Biologics S.A.

Institut de la Vision

Novartis AG

uniQure N.V.

Kite Pharma, Inc.

National Cancer Institute

US Department of Health and Human Services

National Institutes of Health

Arcturus Therapeutics Ltd.

Johnson & Johnson

Johnson & Johnson

Johnson & Johnson

Rodin Therapeutics, Inc.

Clovis Oncology, Inc.

Kadimastem Ltd.

RedHill Biopharma Ltd.

IceCure Medical Ltd.

Antibe Therapeutics, Inc.

SpineGuard SA

Abbott

Acutus Medical, Inc.

NeuroTronik, Inc.

dBMEDx Inc.

Qiagen NV

Provista Diagnostics Inc.

GeneCentric Therapeutics, Inc.

Trice Medical

Perrigo Company PLC

Fera Pharmaceuticals

Abbott

AbbVie Inc.

Alvine Pharmaceuticals, Inc.

Ascletis Pharma, Inc.

Roche Holding AG

InterMune, Inc.

Johnson & Johnson

Johnson & Johnson

Alnylam Pharmaceuticals Inc.

Roche Holding AG

Johnson & Johnson

Additional Topics

Deals BioPharmaceutical Medical Device

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window